Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,283 people get JAZZ articles and Market Currents by email alert.
Get email alerts on JAZZ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1 -
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11 -
-
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012 -
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Jazz Pharmaceuticals Still in TroubleEben Tessari • Thu, Jun 12, 2008
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1
-
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012
-
-
-
-
-
-
-
-
-
3 Growth Mid Cap Stocks To ConsiderSupreme Alpha • Wed, Aug 22, 2012 -
-
-
Jazz Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Jazz Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptFri, Aug 8, 2008
-
Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Mar 19, 2013)
-
at MarketWatch.com (Mar 12, 2013)
-
at CNBC.com (Mar 5, 2013)
-
at MarketWatch.com (Oct 2, 2012)
-
at CNBC.com (Aug 15, 2012)
-
at CNBC.com (May 22, 2012)
-
at MarketWatch.com (Feb 7, 2012)
-
at MarketWatch.com (Jan 24, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
PR Newswire (Jan 5, 2012)
-
PR Newswire (Dec 12, 2011)
-
at CNBC.com (Sep 21, 2011)
-
at CNBC.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 19, 2011)
-
at MarketWatch.com (Sep 8, 2011)
-
at MarketWatch.com (Sep 7, 2011)
JAZZ vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company that, since our inception, has focused on the development and commercialization of pharmaceutical products to meet important unmet medical needs in neurology and psychiatry. With our JZP-6 product candidate for the treatment of fibromyalgia, for which we... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 12:26 PM Jazz Pharmaceuticals (JAZZ -10%) gets slammed in spite of a solid Q1 earnings beat late yesterday, as investors focus on potential changes at the FDA which could lead the way to approving a generic version of JAZZ's narcolepsy medicine Xyrem, which is currently being produced by Roxane. Xyrem generated $117.5M in sales this quarter alone, nearly 60% of its revenue. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, May 7, 4:15 PM Jazz Pharma (JAZZ): Q1 EPS of $1.37 beats by $0.02. Revenue of $196.2M beats by $. Shares +5.1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Monday, March 11, 11:59 AM Jazz Pharmaceuticals (JAZZ +0.9%) moves higher today after Cantor Fitzgerald starts coverage with a Buy rating and $86.00 price target. Cantor calls JAZZ an attractive growth story that's been held back by generic concerns over its key revenue driver, Xyrem, a drug for the treatment of narcolepsy, which represents 69% of revenue. Comment! [Healthcare, On the Move]
- Monday, March 4, 7:00 PM Jazz Pharmaceuticals (JAZZ) announces plans for underwritten public offering of 5.375M shares of its stock held by certain shareholders. JAZZ will not receive any proceeds from the offering. Barclays is acting as sole book-running manager for the offering. Shares -2.1% AH. Comment! [Healthcare, On the Move]
- Tuesday, February 26, 4:35 PM More on Jazz Pharma (JAZZ): Q4 EPS easily beats estimates. Net sales of Xyrem were $113.5M, compared to net sales of $71.8M for Q411. Gross margin was 85.8% compared to 95.2% for 2011. For FY13, the company expects an EPS of $5.70-5.90 on sales of $805M - 835M, above Street estimates of $5.67 on revenue of $811.3M. Shares +2% AH. Comment! [Healthcare, Earnings, On the Move]
- Thursday, November 8, 2012, 4:22 PM Jazz Pharmaceutical (JAZZ): $1.29 misses by $0.03. Revenue of $175M misses by $4M. Shares -1% AH. (PR) 1 Comment [Healthcare, Earnings, On the Move]
- Monday, September 17, 2012, 3:58 PM Shares of Jazz Pharmaceuticals' (JAZZ +15%) jump on a favorable Markman ruling defining the patent claim terms related to its narcolepsy medication Xyrem. Jefferies analyst Corey Davis says upon first read, the patent construction ruling "seems like a clear win for Jazz." Comment! [Healthcare, On the Move]
- Tuesday, August 7, 2012, 4:19 PM Jazz Pharmaceuticals (JAZZ): Q2 EPS of $1.09 beats by $0.04. Revenue of $130M beats by $5M. Shares +2.4% AH. Comment! [Earnings, On the Move]
- Friday, April 27, 2012, 1:37 PM Jefferies says Jazz Pharmaceuticals' (JAZZ +16.6%) acquisition of EUSA will add $0.76 to its FY13 earnings estimate and diversifies the company away from Xyrem. The firm now calls Jazz one of its top picks and raises its price target to $74. Comment! [Quick Ideas, M&A, On the Move]
-
Friday, April 27, 2012, 9:00 AM
Premarket gainers: EXPE +19%. AMZN +17%. JAZZ +15%. CRAY +12%. WCRX +12%. BPZ +6%. CBS +5%. AEM +5%. RTK +5%. ARNA +4%. GT +4%. CLWR +3%. SNY +3%. MT +3%. ARMH +3%.
Losers: MDRX -42%. DECK -19%. WDC -11%. STX -7%. KOG -5%. SBUX -4%. FIO -4%. 4 Comments [On the Move] - Thursday, April 26, 2012, 6:04 PM Jazz Pharmaceuticals (JAZZ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for as much as $700M in cash. EUSA's FDA-approved Erwinaze treatment blocks cell growth in patients with acute leukemia by cutting down asparagine levels in the bloodstream. Jazz expects the deal to add $210M-$230M in revenue and $0.75-$0.85/share in earnings. Comment! [Healthcare, M&A, On the Move]
- Monday, February 27, 2012, 4:25 PM Jazz Pharmaceuticals (JAZZ): Q4 EPS of $1.17 beats by $0.08. Revenue of $83.5M (+56.4% Y/Y) beats by $3M. Shares +2.3% AH. (PR) Comment! [Earnings, On the Move]
- Friday, January 6, 2012, 10:03 AM Jazz Pharmaceuticals (JAZZ +7.9%) double up on its AH gain yesterday following its upward revision for 2012 revenue. Adding to the momentum, analysts at Muzho upped their price target on shares to $62 from $52 based on the firm's rosy outlook. Comment! [Healthcare, On the Move]
- Thursday, January 5, 2012, 4:22 PM Jazz Pharmaceuticals (JAZZ) gains 3.1% AH after guiding for 2012 revenue of $465M-$490M and EPS of $4-$4.15, above a consensus of $462.8M and $3.40. The guidance takes into account Jazz's planned merger with Azur Pharma, which the companies hope to close on Jan. 16 - it's possible not all analyst forecasts took the deal into account. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, October 19, 2011, 7:47 AM Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to an FDA warning letter related to its Xyrem drug. However, Jefferies and Piper have come to Jazz's defense, with each noting that the warning merely involves the company's monitoring procedures, rather than any production issues. Comment! [Healthcare, On the Move, Quick Ideas]
- Tuesday, October 18, 2011, 9:49 AM Jazz Pharmaceuticals (JAZZ -7%) receives an FDA warning letter describing multiple safety violations, including "failure to develop adequate written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences to FDA." Comment! [Healthcare, On the Move]
-
Capitalist Bull
Not much left to do, few setups remain. Patiently hold leading growth stocks through 1st pullbacks. http://stks.co/bV7p $ES_F $JAZZ $OCN - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
-
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 3 replies
-
-
-
smokeyRose
What is up with $JAZZ ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? - View all 2 replies
-
-
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
- View all 2 replies
-
tippycanoes: I bought under a dollar...sold at 6$... it haunts me. Literally could have retired -
-
- View all 14 replies
-
-
-
Michael Bryant
Jazz Pharmaceuticals (JAZZ) keeps rising. Could be good longterm holding. http://yhoo.it/yGLaZa;c= - View all 2 replies
-
-
-
- View all 5 replies
-
-
SlingWing9: They've all got lawsuits against them. All of them have legal depts, all allocate billions/yr for legal issues. Find one TBTF w/o lawsuits
-
- View all 1 replies
-
losbronces: And that is why people still play biotechs even though the odds of success are low.
-
- View all 3 replies
-
-
-
Michael Bryant
Not bad. Jazz Pharma (JAZZ) up 2%. Ulta Salon (ULTA) up 3.27%. Cabot Oil & Gas (COG) up 0.13%. http://seekingalpha.com/a/6rmy - View all 3 replies
-
-
-
- View all 1 replies
-
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.
-
Michael Bryant
Jazz Pharmaceuticals (JAZZ) is rising on unusual volume. It is a definite buy. PE ratio is very low. - View all 2 replies
-
-